Makes ECMO life support machines and hospital sterilization equipment that hospitals cannot easily replace or update.
At a glance
- Depends onDownstream position: depends on 8 industries, supplies 3
- ScaleMarket cap is above the global median
Makes ECMO life support machines and hospital sterilization equipment that hospitals cannot easily replace or update.
What this company is and how it runs — written from structure, not news.
Getinge makes ECMO life support machines and the sterilization equipment that hospitals use to clean surgical instruments, and both sides of the business earn revenue only after passing through the same FDA and EU MDR clinical review process, which takes at least 12 to 18 months for every software update regardless of how much money or engineering effort Getinge puts in. Because each ECMO machine is validated as a matched hardware-software pair, any improvement to the pump control software restarts that clock, so consumables — the disposable oxygenator membranes and ventilator circuits used once per patient — accumulate in the installed base while the company waits to bill for the next feature cycle. On the sterile processing side, the equipment's proprietary sensors feed validated cycle data directly into a hospital's Joint Commission accreditation, which means ripping out the hardware would require the hospital to go through a full re-inspection, so competitors cannot win the business simply by offering equivalent machines. The single thing that could unravel both businesses at once is an IT architecture change — if a hospital replaces its electronic records system in a way that severs the live data connection between the sterilization chambers and its quality management software, the accreditation built around that data flow becomes unverifiable, and the lock-in disappears at the moment the hospital's IT team makes the switch rather than at any point Getinge controls.
How does this company make money?
The company sells ECMO machines, mechanical ventilators, and sterilization systems directly to hospitals. Once that equipment is installed, hospitals must keep buying disposable parts — oxygenator membranes, ventilator circuits, and sterilization indicators — for every patient treated or every sterilization cycle run. Those consumables cannot be substituted from another supplier without triggering a full re-validation, so each installed machine generates a reliable and ongoing stream of repeat purchases.
What makes this company hard to replace?
Connecting a new ECMO or ventilator system to existing ICU monitoring equipment requires a clinical validation period of 6 to 12 months before the hospital can use it in practice. Sterilization department workflows are written into the hospital's quality accreditation, and changing that equipment means going through a full Joint Commission re-inspection. For pharmaceutical manufacturers, FDA process validation ties their manufacturing licence to the specific sterilization equipment already installed, so replacing it means re-validating the entire production process.
What limits this company?
Every software improvement across the ECMO, ventilator, and sterilization platforms must go through an FDA and EU MDR review before it can generate revenue. That review takes a minimum of 12 to 18 months no matter how many engineers the company hires or how much money it spends. So the gap between finishing a new feature and getting paid for it is fixed by regulation, not by anything the company controls.
What does this company depend on?
The company cannot operate without FDA 510(k) clearances for its ECMO devices and mechanical ventilators, CE marking under the EU Medical Device Regulation, and ISO 13485 certification covering its manufacturing quality systems. It also relies on suppliers of specialized biocompatible polymers used in ECMO tubing and oxygenator membranes, and on hospital group purchasing organization contracts in North America and Europe to reach its main customers.
Who depends on this company?
Cardiac surgery departments at academic medical centers depend on this company's ECMO systems to support patients through high-risk procedures — without them, those procedures could not be safely performed. Central sterile supply departments in hospitals would face FDA compliance violations if they lost access to the validated sterilization equipment. ICU departments would lose mechanical ventilation capacity during surges in respiratory illness. Pharmaceutical companies running vaccine production would be forced to halt operations if the biocontainment sterilization systems went offline.
How does this company scale?
The software platforms that connect sterilization chambers to hospital systems, and the algorithms that run sterilization cycles, can be deployed across many hospital sites without meaningful extra cost for each new installation. What does not get cheaper as the company grows is regulatory validation — every modification to any device still requires the same FDA and EU MDR clinical evidence process, taking the same 12 to 18 months regardless of how large the company becomes.
What external forces can significantly affect this company?
European Central Bank monetary policy affects the strength of the Swedish krona against the US dollar and the euro, which changes how competitive the company's global prices are. CMS reimbursement rate changes for ECMO procedures directly affect how much budget hospitals have for capital equipment purchases. The EU Medical Device Regulation has raised the bar for clinical evidence beyond what the older MDD rules required, increasing the cost and time needed to bring products to the European market.
Where is this company structurally vulnerable?
If a hospital upgrades its electronic medical records platform or tightens its cybersecurity rules in a way that cuts the live data connection between the sterilization chambers and the hospital's information systems, the cycle records stop flowing. Without those live records, the Joint Commission accreditation built around them cannot be verified. At that point, the reason a hospital cannot swap out the equipment disappears — and it disappears because of an IT decision inside the hospital, not anything the company can prevent.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
The reported statements, read against the company's own industry.
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Three multi-year observations co-occur: revenue increased year-over-year in each of the last three fiscal years, gross profit (absolute level) increased year-over-year in each of the last four fiscal years, and net income was positive in each of the last five fiscal years. The configuration describes growth-and-profitability persistence across three different windows.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph